The FDA approved two oncology regimens on Jan. 16.One is for a subset of patients with colorectal cancer and the other for ...

The FDA also approved Qiagen's Therascreen KRAS RGQ PCR kit as a companion diagnostic to identify KRAS G12C-mutant patients.

The CodeBreaK 300 results demonstrated that Lumakras 960 mg daily plus Vectibix (n=53) showed an improved median ...

Pivotal Study Demonstrated the Combination More Than Doubled Progression-Free Survival Compared to Investigated SOC THOUSAND OAKS, Calif., Jan. 17, 2025 /PRNewswire/ ...

SightMD Connecticut is pleased to announce its acquisition of Doctor & Associates, a trusted provider of advanced eye care services in Fairfield County since 1965. This strategic partnership marks a ...

THOUSAND OAKS, Calif. - Amgen (NASDAQ:AMGN), a prominent biotechnology company with a market capitalization of $144.8 billion, has received FDA approval for LUMAKRAS® (sotorasib) in combination with ...

Approval was based on the pivotal Phase 3 CodeBreaK 300 study.

Our Expert Doc ( celebrated a successful 2024 launch of its secure, HIPAA-compliant online medical consultation platform. This globally accessible platform provides patients worldwide with access ...

The US Food and Drug Administration approved sotorasib (trade name Lumakras) with panitumumab Vectibix), from US biotech ...

"The CDC must be investigated for its misuse of PEPFAR funds," said Sen. Jim Risch (R-Idaho), following a report that funds ...

The combination treatment specifically targets KRAS-mutated metastatic colorectal cancer (CRC) to improve progression-free ...

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved LUMAKRAS® (sotorasib) in ...